Programme Overview

ILCA 2019 / Programme Overview
Pre-Conference
General Session
Symposium
State-of-the-Art Lecture
Industry Symposium
Workshops

13:00 – 18:15

ILCA Pre-Conference Workshop on Metabolism and Liver Cancer: From Mechanism to Treatment

Chairs: Valerie Paradis, MD, PhD (France), Jean-François Dufour, MD, PhD (Switzerland) and Amit Singal, MD (USA)

13:00 – 13:25

  • Mouse Models and Lessons Learned for HCC in NAFLD
    Shabnam Shalapour, PhD (USA)

13:25 – 13:50

  • Molecular Characterisation of HCC in NAFLD
    Josep M. Llovet, MD, PhD (Spain/USA)

13:50 – 14:15

  • Role of the Immune System in NAFLD Related Hepatocarcinogenesis
    Tim Greten, MD (USA)

14:15 – 14:35

Panel Discussion

14:35 – 15:00

  • Assessment of Risk for HCC in NAFLD Patients
    Jean-Francois Dufour, MD, PhD (Switzerland)

15:00 – 15:25

  • Recent Trends in Epidemiology of NASH-Related HCC
    Kathryn McGlynn, PhD (USA)

15:25- 15:50

  • Locoregional Therapies − Including Ablation − for HCC in Patients with NAFLD
    Anja Lachenmayer, MD (Switzerland)

15:50 – 16:15

  • Resection and Transplant for HCC in Patients with NAFLD
    Julie Heimbach, MD (USA)

16:15 – 16:35

Panel Discussion

16:35 – 17:00

  • Issues with Surveillance in NASH Population
    Amit Singal, MD (USA)

17:00 – 17:25

  • Pathologic Characterization of HCC in NASH and Impact on Biomarker Discovery/Therapeutics
    Valerie Paradis, MD, PhD (France)

17:25 – 17:50

  • Future Directions in Imaging and Biomarker-Based HCC Surveillance in NAFLD-Related Liver Disease
    Sven Francque, MD, PhD (Belgium)

17:50 – 18:15

Panel Discussion

The pre-conference workshop is subject to an additional registration. To attend this workshop, full conference registration is compulsory.

18:30 – 19:30

Young Investigator Session

Chairs: Maria Reig, MD, PhD (Spain) and Jean-Charles Nault, MD (France)

  • How to Publish in Journal of Hepatology?
    Bruno Sangro, MD, PhD (Spain)

08:00 – 09:30

ILCA Symposium 1: The Cell of Origin of Liver Cancer

Chair: Augusto Villanueva, MD, PhD (USA)

  • Hepatocytes, Cholangiocytes, Stem Cells, etc. Who to Blame for Liver Cancer Development?
    Lars Zender, MD, PhD (Germany)
  • Why Inflammation and Regeneration are Key to Liver Cancer Development?
    Nabil Djouder, PhD (Spain)
  • Cell of Origin in Human Samples: Lessons from Genomic Studies
    Anuradha Budhu, PhD (USA)

09:30 – 10:15

State-of-the-Art Lecture 1: The Patient Perspective on Cancer Treatment

Chair: Morris Sherman, MD, PhD (Canada)
Speaker: Melinda Bachini (USA)

10:15 – 10:45

Coffee and Networking Break

10:45 – 11:00

Welcome Address

Morris Sherman, MD, PhD (Canada), Jessica Zucman-Rossi, MD, PhD (France), Sandrine Faivre, MD, PhD (France) and Bruno Sangro, MD, PhD (Spain)

11:00 – 12:30

General Session 1: Molecular Pathogenesis

12:30 – 12:45

Session Break

12:45 – 14:15

Industry Partner Lunch Symposium

14:15 – 14:30

Session Break

14:30 – 16:00

General Session 2: Clinical Trials

16:00 – 16:45

Coffee and Networking Break

16:00 – 16:45

ILCA General Assembly (members only)

16:45 – 18:15

ILCA Symposium 2: Peri Hilar Cholangiocarcinoma

Chairs: Eric Vibert, MD, PhD (France) and Christian Toso, MD, PhD (Switzerland)

  • Patient Selection and Optimization for Surgery
    Masato Nagino, MD (Japan)
  • Resection or Transplantation for Cholangiocarcinoma
    Julie Heimbach, MD (USA)
  • Histological and Morphological Heterogeneity of Biliary Stenosis
    Tom H. Karlsen, MD, PhD (Norway)

18:15 – 19:15

Industry Partner Symposium

19:15 – 20:00

Welcome Reception

07:30 – 08:30

Industry Partner Symposium

08:30 – 9:45

ILCA − EASL Symposium

  • Assessment of Risk and Decision Analysis
    Pierre Nahon, MD, PhD (France)
  • Risk Assessment for Outcomes Following Potentially Curative Treatments for HCC
    Francis Yao, MD (USA)
  • Assessing Risk of Bad Outcomes Following TACE and Systemic Therapy
    Maria Reig, MD, PhD (Spain)

09:45 – 10:45

Networking Break and e-Poster Viewing Tour

10:45 – 12:00

Presidential Session

Chairs: Morris Sherman, MD, PhD (Canada), Jessica Zucman-Rossi, MD, PhD (France), Sandrine Faivre, MD, PhD (France) and Bruno Sangro, MD, PhD (Spain)

12:00 – 12:15

Session Break

12:15 – 13:45

Industry Partner Lunch Symposium

13:45 – 14:00

Session Break

14:00 – 15:15

Ground Rounds Session

Multidisciplinary Case Presentations and Debate
Chair: Laura Kulik, MD (USA)
Expert Panel: Neehar Parikh, MD (USA), Gonzalo Sapisochin, MD, PhD (Canada) and Masatoshi Kudo MD, PhD (Japan)
Speaker: Jasmine Sinha, MD (USA)

15:15 – 15:45

Coffee and Networking Break

15:45 – 17:15

General Session 3: Epidemiology, Diagnosis, Staging

17:15 – 17:30

Session Break

16:30 – 18:30

Workshop for Nurses

Chair: HoChong Gilles (USA)

  • Liver Lesions 101
    Barbara Andrews (USA)
  • Surgical and Locoregional Treatment Options for HCC
    HoChong Gilles (USA)
  • New Systemic Therapies for Advanced HCC
    Vicki Shah (USA)
  • Panel Discussion − Multi-Disciplinary Tumor Board: A Case-Based Approach
    HoChong Gilles (USA), Barbara Andrews (USA) and Vicki Shah (USA)
  • Q&A Session
    HoChong Gilles (USA), Barbara Andrews (USA) and Vicki Shah (USA)

17:30 – 18:30

ILCA Single Topic Workshops (STW)

STW 1: Molecular Diversity in HCC
Novel Models to Explore Molecular Diversity in HCC
Amaia Lujambio, PhD (USA) and Jean-Charles Nault, MD (France)

STW 2: Systemic Therapy
How to Sequence Treatment
Britsi Basu, MD, PhD (UK) and Andrew Zhu, MD, PhD (USA)

STW 3: Surgery for Primary Liver Cancer
Transplantation for Cholangiocarcinoma
Lewis Roberts, MD, PhD (USA) and Eric Vibert, MD, PhD (France)

STW 4: Radiology
Imaging of HCC Response to Loco-Regional and Systemic Therapy
Riccardo Lencioni, MD (Italy/USA) and Tae Kyoung Kim, MD, PhD (Canada)

18:30 – 19:30

Industry Partner Workshops

19:30 – 20:30

Industry Partner Symposium

08:00 – 09:00

Industry Partner Symposium

09:00 – 10:15

ILCA − AASLD Symposium

Chairs: Jessica Zucman-Rossi, MD, PhD (France) and Josep M. Llovet, MD, PhD (Spain/USA)

  • End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate and Advanced HCC
    Richard Finn, MD (USA)
  • Immunotherapy for HCC: What’s Next?
    Anthony El-Khoueiry, MD (USA)
  • Pathogenesis and Systemic Management of iCCA: Role of Molecular Therapies
    Gregory Gores, MD (USA)

10:15 – 10:45

State-of-the-Art Lecture 2: Molecular Lessons Learnt from Clinical Trials in the Last Decade

Speaker: Andrew Zhu, MD, PhD (USA)

10:45 – 11:00

Coffee and Networking Break

11:00 – 12:30

General Session 4: Novel Targets and Prognostics Markers

12:30 – 12:45

Closing Ceremony

Contact Us

Keep Me Updated

By continuing to browse this website, you accept cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close